JPM vs MMD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MMD presents a high-risk profile characterized by a stable Piotroski F-Score of 5/9 but severe valuation disconnects. The current price of $14.88 trades at a massive premium to both the Graham Number ($6.08) and the Intrinsic Value ($1.51). Financial stability is undermined by a catastrophic dividend payout ratio of 720%, indicating that distributions are not supported by earnings. Combined with negative revenue growth (-15%) and a bearish technical trend (0/100), the fund appears fundamentally overvalued.
Compare Another Pair
Related Comparisons
JPM vs MMD: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and NYLI MacKay DefinedTerm Muni Opportunities Fund (MMD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.